Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGONAUT trial
2024-512685-33-00Phase 3Authorised
- Sponsor
- CHU Nîmes
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban, dabigatran, apixaban, warfarin, fluindione and 1 more in intracardiac thrombosis (2 arms), sponsored by CHU Nîmes. Primary endpoint: Net clinical benefit at 6 months. Planned start May 2024; status: authorised.
02
Drugs
rivaroxabandabigatranapixabanwarfarinfluindione
03
Conditions
intracardiac thrombosis
Beyond the preview
Go deeper on 2024-512685-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512685-33-00.